Search Result

Results for "

glutamate transporter

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EAAT (23) iGluR (3) mGluR (2) Akt (1) Antibiotic (5) Apoptosis (2) Bacterial (5) Biochemical Assay Reagents (1) Casein Kinase (1) Dopamine Transporter (1) Drug Derivative (1) ERK (1) Ferroptosis (2) GlyT (2) HIV (1) Isotope-Labeled Compounds (2) NF-κB (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) Sodium Channel (1) Wnt (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (3) Infection (5) Metabolic Disease (2) Neurological Disease (31)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Targets Recommended: Glutamate Dehydrogenase (GLDH) EAAT mGluR iGluR

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-B1102

Evans Blue 25+ Cited Publications Direct Blue 53; T-1824; C.I. 23860	EAAT iGluR	Cardiovascular Disease Neurological Disease
Evans Blue (Direct Blue 53) is a potent inhibitor of L-glutamate uptake via the membrane bound *excitatory amino acid transporter* (EAAT). Evans Blue is a L-glutamate and kainate receptor**-mediated currents inhibitor. Evans Blue has a strong affinity towards serum albumin, making it a high molecular weight protein tracer. Evans Blue is also used to study BBB (blood-brain barrier) permeability .

HY-100784

Dihydrokainic acid 1 Publications Verification	EAAT	Neurological Disease
Dihydrokainic acid is a **glutamate transporters (especially GLT1*) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport* function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory .

HY-B1190

Cefadroxil 5 Publications Verification BL-S 578	Bacterial Antibiotic EAAT	Infection Neurological Disease
Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of **glutamate transporter-1*. Cefadroxil is dependent on the intestinal peptide transporter* PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

HY-139087

Erastin2 5 Publications Verification	Ferroptosis	Metabolic Disease
Erastin2, an Erastin (HY-15763) analog, is a ferroptosis inducer and a potent, selective inhibitor of the system xc(-) cystine/glutamate transporter

HY-107522

DL-TBOA 1 Publications Verification	EAAT	Neurological Disease
DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC₅₀s of 70 μM, 6 μM and 6 μM for *excitatory amino acid transporter-1 (EAAT1), EAAT2* and EAAT3, respectively. DL-TBOA inhibits the uptake of [ ¹⁴C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K_i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with K_i values of 4.4 μM and 3.2 μM, respectively .

HY-Y1147

Diethyl maleate 1 Publications Verification Maleic acid diethyl ester	Biochemical Assay Reagents	Others
Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter X_{O ^-}. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].

HY-107661

Arundic Acid 2 Publications Verification ONO-2506; (R)-2-Propyloctanoic acid	ERK Akt NF-κB EAAT	Cardiovascular Disease Neurological Disease
Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy .

HY-12741

LDN-212320 5+ Cited Publications LDN-0212320; OSU-0212320	EAAT	Neurological Disease
LDN-212320 (LDN-0212320) is a glutamate transporter (GLT-1)/*excitatory amino acid transporter* 2 (EAAT2)** activator (at translational level). LDN-212320 (LDN-0212320) prevents nociceptive pain by upregulating astroglial GLT-1 expression in the hippocampus and ACC ^[1]

HY-107521

TFB-TBOA 3 Publications Verification CF3-Bza-TBOA	EAAT	Neurological Disease
TFB-TBOA (CF3-Bza-TBOA) is a potent **glutamate transporter** blocker that potently suppresses the activity of glial transporters. TFB-TBOA shows IC₅₀ values of 22, 17, and 300 nM for glutamate transporters EAAT1, EAAT2, and EAAT3 respectively in an uptake assay using cells transiently expressing EAATs .

HY-162455

NA-014	EAAT	Neurological Disease
NA-014 is an *excitatory amino acid transporter* 2 (EAAT2*)-selective positive allosteric modulator. NA-014 increases EAAT2-mediated glutamate* uptake. NA-014 can be used for the research of epilepsy, neuropathic pain, stroke, drugs of abuse disorders .

HY-B1190A

Cefadroxil hydrate 5 Publications Verification BL-S 578 hydrate	Bacterial Antibiotic EAAT	Infection Neurological Disease
Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of **glutamate transporter-1*. Cefadroxil hydrate is dependent on the intestinal peptide transporter* PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

HY-124619

GPI-1046	EAAT HIV	Neurological Disease
GPI-1046 is an orally active, antibiotic-free immunophilin ligand that reduces ethanol intake by upregulating glutamate transporter 1 (GLT1) in the prefrontal cortex (PFC) and nucleus accumbens core (NAc-core). GPI-1046 improves human immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN) by attenuating store-operated calcium (SOC) entry. GPI-1046 has neuroprotective activity .

HY-139692

EAAT2 activator 1	EAAT	Neurological Disease
EAAT2 activator 1 is the potent activator of *excitatory amino acid transporter* 2 (EAAT2*). EAAT2 is the major glutamate* transporter and functions to remove glutamate from synapses. EAAT2 activator 1 increases EAAT2 protein levels dose-dependently .

HY-21045

5-Fluoro-L-tryptophan L-5-Fluorotryptophan	EAAT	Neurological Disease
5-Fluoro-L-tryptophan is a competitive vesicular glutamate transporter (VGLUT) inhibitor. 5-Fluoro-L-tryptophan is promising for research of diseases associated with the neurotransmitter systems .

HY-100836

trans-4-Carboxy-L-proline	iGluR	Neurological Disease
Trans-4-Carboxy-L-prolineis a selective glutamate transporter inhibitor .

HY-131286A

Talaglumetad (hydrochloride) LY-544344 (hydrochloride)	Drug Derivative mGluR	Neurological Disease
Talaglumetad hydrochloride (LY-544344 hydrochloride) is an orally active prodrug of Eglumegad (HY-18941) and a *metabotropic glutamate* receptor 2/3 (mGluR2/3)** agonist. Talaglumetad hydrochloride undergoes transmembrane transport via the intestinal peptide transporter hPepT1, and is enzymatically hydrolyzed to produce L-alanine and the parent drug Eglumegad after entering the body. Talaglumetad hydrochloride can be used in research related to metabotropic glutamate receptor 2-associated neurological systems .

HY-W585874

Nε-(Carboxyethyl)lysine	EAAT Apoptosis	Neurological Disease Metabolic Disease
Nε-(Carboxyethyl) lysine is an advanced glycation end product (AGE). Nε-(Carboxyethyl) lysine induces cross-linking between proteins, thereby affecting protein structure and function and causing protein denaturation. Nε-(Carboxyethyl) lysine binds to the RAGE receptor, affects cell signal transduction, and regulates processes such as inflammatory responses, cell proliferation, and apoptosis. Nε-(Carboxyethyl) lysine affects glutamate transporters, reduces glutamate uptake and S100β protein secretion, influences neurotransmission in the nervous system, and exhibits diabetes-related neurotoxicity .

HY-133177

MS-153	EAAT	Neurological Disease
MS-153 is a **glutamate transporter** activator that can be used as a neuroprotective agent .

HY-B1190R

Cefadroxil (Standard) BL-S 578 (Standard)	Reference Standards Bacterial Antibiotic EAAT	Infection Neurological Disease
Cefadroxil (Standard) is the analytical standard of Cefadroxil (HY-B1190). This product is intended for research and analytical applications. Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of **glutamate transporter-1*. Cefadroxil is dependent on the intestinal peptide transporter* PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

HY-B1190S

Cefadroxil-d4 hydrate BL-S 578-d4 hydrate	Isotope-Labeled Compounds Bacterial Antibiotic EAAT	Infection Neurological Disease
Cefadroxil-d₄ (hydrate) is the deuterium labeled Cefadroxil hydrate (HY-B1190A). Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of **glutamate transporter-1*. Cefadroxil hydrate is dependent on the intestinal peptide transporter* PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

HY-175296

EAAT2 activator 2	EAAT	Neurological Disease
EAAT2 activator 2 (Compound 4(SF-2)) is a brain-penetrant excitatory amino acid transporter 2 (EAAT2) modulator (K_i=28.7 nM). EAAT2 activator 2 enhances EAAT2-mediated glutamate uptake, improving synaptic glutamate clearance. EAAT2 activator 2 is promising for research of neurodegenerative diseases (e.g., ALS, Alzheimer’s disease) .

HY-107522B

DL-TBOA ammonium	EAAT	Neurological Disease
DL-TBOA ammonium is a potent non-transportable inhibitor of excitatory amino acid transporters with IC₅₀s of 70 μM, 6 μM and 6 μM for *excitatory amino acid transporter-1 (EAAT1), EAAT2* and EAAT3, respectively. DL-TBOA ammonium inhibits the uptake of [ ¹⁴C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K_i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA ammonium blocks EAAT4 and EAAT5 in a competitive manner with K_i values of 4.4 μM and 3.2 μM, respectively .

HY-101334

MPDC	GlyT	Neurological Disease
MPDC is a potent and competitive inhibitor of the Na ⁺-dependent high-affinity **glutamate transporter** in forebrain synaptosomes .

HY-101334A

MPDC hydrochloride	GlyT	Neurological Disease
MPDC hydrochloride is a potent and competitive inhibitor of the Na ⁺-dependent high-affinity **glutamate transporter** in forebrain synaptosomes .

HY-100616

cis-ACBD cis-1-Aminocyclobutane-1,3-dicarboxylic acid	Sodium Channel	Neurological Disease
cis-ACBD is a potent and selective inhibitor of the high-affinity, Na ⁺-dependent plasma membrane **glutamate transporter*. cis-ACBD is a glutamate* reuptake inhibitor. cis-ACBD also acts as linear competitive inhibitor of the uptake of D-[3H]aspartate .

HY-100838

cis-α-(Carboxycyclopropyl)glycine L-CCG III	EAAT	Neurological Disease
cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC₅₀: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na ⁺-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes .

HY-100784R

Dihydrokainic acid (Standard)	Reference Standards EAAT	Neurological Disease
Dihydrokainic acid (Standard) is the analytical standard of Dihydrokainic acid. This product is intended for research and analytical applications. Dihydrokainic acid (DHK) is a glutamate transporter GLT1 (EAAT2) inhibitor. Dihydrokainic acid impairs novel object recognition (NOR) memory performance in mice. Dihydrokainic acid also shows epileptogenic effects .

HY-B1190S2

Cefadroxil-13C6 BL-S 578-¹³C₆	Isotope-Labeled Compounds Bacterial Antibiotic EAAT	Infection Neurological Disease
Cefadroxil- ¹³C₆ (BL-S 578- ¹³C₆) is ¹³C labeled Cefadroxil (HY-B1190). Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of **glutamate transporter-1*. Cefadroxil is dependent on the intestinal peptide transporter* PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

HY-161062

TAOA AM Ester trimethyl lock	EAAT	Neurological Disease
TAOA AM Ester trimethyl lock is a high-affinity fluorescent prodrug-like inhibitor of the excitatory amino acid transporter (EAAT). It can penetrate the cell membrane and be activated by hydrolysis by endogenous cell esterases to form active EAAT inhibitors. TAOA AM Ester trimethyl lock can be used to study neurodegeneration and neuronal cell death .

HY-183588

HCM-01	EAAT Reactive Oxygen Species (ROS)	Neurological Disease
HCM-01 is an *Excitatory amino acid transporter* 2 (EAAT2*) activator with oral effectiveness and blood-brain barrier penetration.HCM-01 binds to the allosteric site of EAAT2, increases EAAT2 expression in astrocytes, enhances glutamate-handling capacity, and modulates glutamate* homeostasis.HCM-01 acts as an antioxidant, improves oxidative/antioxidative balance and increases total antioxidant capacity. HCM-01 can be used for the research of Alzheimer's disease .

HY-131286

Talaglumetad LY-544344	mGluR	Neurological Disease
Talaglumetad (LY-544344) is an orally active prodrug of Eglumegad (HY-18941) and a *metabotropic glutamate* receptor 2/3 (mGluR2/3)** agonist. Talaglumetad undergoes transmembrane transport via the intestinal peptide transporter hPepT1, and is enzymatically hydrolyzed to produce L-alanine and the parent drug Eglumegad after entering the body. Talaglumetad can be used in research related to metabotropic glutamate receptor 2-associated neurological systems .

HY-12879G

IWP-4	Wnt Casein Kinase	Cardiovascular Disease Neurological Disease Cancer
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

HY-182067

anti-TNBC agent-15	Reactive Oxygen Species (ROS) Apoptosis Ferroptosis	Cancer
anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .

HY-183324

AMPA receptor modulator-12	iGluR Dopamine Transporter	Neurological Disease
AMPA receptor modulator-12 is an orally acrive AMPA receptor positive allosteric modulator. AMPA receptor modulator-12 also exhibits moderate binding affinity for the human dopamine transporter with a K_d of 1.57 μM. AMPA receptor modulator-12 enhances AMPA receptor-mediated ion currents, delays channel deactivation. AMPA receptor modulator-12 prolongs sleep latency, reduces sleep duration, extends forced swimming time, improves rotarod endurance, and alleviates acute sleep deprivation-related behavioral deficits. AMPA receptor modulator-12 does not increase spontaneous locomotion. AMPA receptor modulator-12 can be used for the research of narcolepsy and fatigue-related conditions .

Cat. No.	상품명

HY-L064

Glutamine Metabolism Compound Library	1,690 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

1,690 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	상품명	Type

HY-12879G

IWP-4	Fluorescent Dyes
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

IWP-4

Fluorescent Dyes

IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

Cat. No.	상품명	Type

HY-B1102

Evans Blue 25+ Cited Publications Direct Blue 53; T-1824; C.I. 23860	Biochemical Assay Reagents
Evans Blue (Direct Blue 53) is a potent inhibitor of L-glutamate uptake via the membrane bound *excitatory amino acid transporter* (EAAT). Evans Blue is a L-glutamate and kainate receptor**-mediated currents inhibitor. Evans Blue has a strong affinity towards serum albumin, making it a high molecular weight protein tracer. Evans Blue is also used to study BBB (blood-brain barrier) permeability .

Evans Blue

25+ Cited Publications

Direct Blue 53; T-1824; C.I. 23860

Biochemical Assay Reagents

Evans Blue (Direct Blue 53) is a potent inhibitor of L-glutamate uptake via the membrane bound excitatory amino acid transporter (EAAT). Evans Blue is a L-glutamate and kainate receptor-mediated currents inhibitor. Evans Blue has a strong affinity towards serum albumin, making it a high molecular weight protein tracer. Evans Blue is also used to study BBB (blood-brain barrier) permeability .

HY-Y1147

Diethyl maleate 1 Publications Verification Maleic acid diethyl ester	Biochemical Assay Reagents
Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter X_{O ^-}. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].

Diethyl maleate

1 Publications Verification

Maleic acid diethyl ester

Biochemical Assay Reagents

Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter X_{O ^-}. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].

HY-12879G

IWP-4	Biochemical Assay Reagents
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

IWP-4

Biochemical Assay Reagents

Cat. No.	상품명	Target	Research Area

HY-100838

cis-α-(Carboxycyclopropyl)glycine L-CCG III	EAAT	Neurological Disease
cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC₅₀: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na ⁺-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes .

Cat. No.	Compare	상품명	Species	Source	Image

HY-P702444

	SLC7A11 Protein, Human (Cell-Free, His) 1 Publications Verification Cystine/glutamate transporter; Amino acid transport system xc-; Calcium channel blocker resistance protein CCBR1; Solute carrier family 7 member 11; xCT	Human	E. coli Cell-free
	The SLC7A11 protein forms a heterodimer with SLC3A2 and acts as an antiporter to exchange extracellular L-cystine for intracellular L-glutamate across the plasma membrane. This sodium-independent electroneutral transport, with a 1:1 stoichiometry, relies on high intracellular levels of L-glutamate and intracellular reduction of L-cystine. SLC7A11 Protein, Human (Cell-Free, His) is the recombinant human-derived SLC7A11 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Cat. No.	상품명	Chemical Structure

HY-B1190S

Cefadroxil-d4 hydrate

Cefadroxil-d₄ (hydrate) is the deuterium labeled Cefadroxil hydrate (HY-B1190A). Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

HY-B1190S2

Cefadroxil-13C6

Cefadroxil- ¹³C₆ (BL-S 578- ¹³C₆) is ¹³C labeled Cefadroxil (HY-B1190). Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .

Host:	Rat (1) Mouse (1) Rabbit (7)
Reactivity:	Human (6) Rat (8) Mouse (9)
Application:	IHC-P (7) ICC/IF (3) IP (4) IHC-F (2) WB (9) ELISA (2)
Isotype:	IgG (7) IgG1 (2)
Conjugation:	Non-conjugated (9)
Clonality:	Monoclonal (9) Recombinant (7)
Modification:	Unmodified (9)

Cat. No.	Compare	상품명	Application	Reactivity	Image

HY-P82737

	EAAT2 Antibody (YA2482) Excitatory amino acid transporter 2; glutamate/aspartate transporter II; Sodium-dependent glutamate/aspartate transporter 2; Solute carrier family 1 member 2	WB, IP	Human, Mouse, Rat
	EAAT2 Antibody (YA2482) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EAAT2.

HY-P82620

	EAAT3 Antibody (YA2365) SLC1A1; EAAC1; EAAT3; Excitatory amino acid transporter 3; Excitatory amino-acid carrier 1; Neuronal and epithelial glutamate transporter; Sodium-dependent glutamate/aspartate transporter 3; Solute carrier family 1 member 1	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	EAAT3 Antibody (YA2365) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EAAT3.

HY-P82734

	EAAT1 Antibody (YA2479) SLC1A3; EAAT1; GLAST; GLAST1; Excitatory amino acid transporter 1; Sodium-dependent glutamate/aspartate transporter 1; GLAST-1; Solute carrier family 1 member 3	WB, IHC-P	Human, Mouse, Rat
	EAAT1 Antibody (YA2479) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EAAT1.

HY-P86606

	EAAT1 Antibody (YA6298) SLC1A3; EAAT1; GLAST; GLAST1; Excitatory amino acid transporter 1; Sodium-dependent glutamate/aspartate transporter 1; GLAST-1; Solute carrier family 1 member 3	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	EAAT1 Antibody (YA6298) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EAAT1.

HY-P80935

	xCT Antibody (YA006) 10+ Cited Publications CCBR1; Cysteine/glutamate transporter; SLC7A11; solute carrier family 7; xCT	WB, IP	Human, Mouse
	xCT Antibody (YA006) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to xCT.

HY-P86499

	xCT Antibody (YA6191) Cystine/glutamate transporter; Amino acid transport system xc-; Calcium channel blocker resistance protein CCBR1; Solute carrier family 7 member 11; xCT;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	xCT Antibody (YA6191) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to xCT.

HY-P87141

	VGluT1 Antibody (YA6834) BNPI antibody; Brain specific Na (+) dependent inorganic phosphate cotransporter antibody; Brain specific Na dependent inorganic phosphate cotransporter antibody; Brain-specific Na(+)-dependent inorganic phosphate cotransporter antibody; Slc17a7 antibody; Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 antibody; Solute carrier family 17 member 7 antibody; Vesicular glutamate transporter 1 antibody; VGLU1_HUMAN antibody; VGLUT 1 antibody; BNPI antibody; Brain specific Na (+) dependent inorganic phosphate cotransporter antibody; Brain specific Na dependent inorganic phosphate cotransporter antibody; Brain-specific Na(+)-dependent inorganic phosphate cotransporter antibody; Slc17a7 antibody; Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 antibody; Solute carrier family 17 member 7 antibody; Vesicular glutamate transporter 1 antibody; VGLU1_HUMAN antibody; VGLUT 1 antibody; VGluT1 antibody;	WB, IHC-P, IHC-F	Mouse, Rat
	VGluT1 Antibody (YA6834) is a Rat -derived and non-conjugated IgG1 monoclonal antibody, targeting to VGluT1.

HY-P87140

	VGluT1 Antibody (YA6833) BNPI antibody; Brain specific Na (+) dependent inorganic phosphate cotransporter antibody; Brain specific Na dependent inorganic phosphate cotransporter antibody; Brain-specific Na(+)-dependent inorganic phosphate cotransporter antibody; Slc17a7 antibody; Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 antibody; Solute carrier family 17 member 7 antibody; Vesicular glutamate transporter 1 antibody; VGLU1_HUMAN antibody; VGLUT 1 antibody; BNPI antibody; Brain specific Na (+) dependent inorganic phosphate cotransporter antibody; Brain specific Na dependent inorganic phosphate cotransporter antibody; Brain-specific Na(+)-dependent inorganic phosphate cotransporter antibody; Slc17a7 antibody; Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 antibody; Solute carrier family 17 member 7 antibody; Vesicular glutamate transporter 1 antibody; VGLU1_HUMAN antibody; VGLUT 1 antibody; VGluT1 antibody;	WB, IHC-P	Mouse, Rat
	VGluT1 Antibody (YA6833) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to VGluT1.

HY-P87139

	VGLUT2 Antibody (YA6832) Differentiation associated BNPI antibody; Differentiation associated Na dependent inorganic phosphate cotransporter antibody; Differentiation associated Na(+) dependent inorganic phosphate cotransporter antibody; Differentiation-associated BNPI antibody; Differentiation-associated Na(+)-dependent inorganic phosphate cotransporter antibody; DNPI antibody; SLC17A6 antibody; Sodium dependent inorganic phosphate cotransporter antibody; Solute carrier family 17 (Sodium dependent inorganic phosphate cotransporter) member 6 antibody; Solute carrier family 17 member 6 antibody; Differentiation associated BNPI antibody; Differentiation associated Na dependent inorganic phosphate cotransporter antibody; Differentiation associated Na(+) dependent inorganic phosphate cotransporter antibody; Differentiation-associated BNPI antibody; Differentiation-associated Na(+)-dependent inorganic phosphate cotransporter antibody; DNPI antibody; SLC17A6 antibody; Sodium dependent inorganic phosphate cotransporter antibody; Solute carrier family 17 (Sodium dependent inorganic phosphate cotransporter) member 6 antibody; Solute carrier family 17 member 6 antibody; Vesicular glutamate transporter 2 antibody; Vesicular glutamate transporter type 2 antibody; VGLU2_HUMAN antibody; VGLUT 2 antibody; VGluT2 antibody;	WB, IHC-F, IHC-P	Mouse, Rat
	VGLUT2 Antibody (YA6832) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to VGLUT2.

Compare Products


Products	해외재고보유 - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / 해외재고보유 - + 장바구니에 담기 견적 받기

Targets Recommended: Glutamate Dehydrogenase (GLDH) EAAT mGluR iGluR

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-12879G

IWP-4	Wnt Casein Kinase	Cardiovascular Disease Neurological Disease Cancer
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC₅₀ of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC₅₀ of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC₅₀ = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: